Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.81 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
67 68 Next >
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
From Bristol Myers Squibb
Via Business Wire
3 Dividend Stocks Trading at 52-Week Lows
All three of these companies have seen brighter days. 
Via The Motley Fool
Insiders Buying Bristol-Myers Squibb And 3 Other Stocks
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Why Bristol Myers Squibb's Shares Are Gaining Today?
Bristol Myers Squibb & Co (NYSE: BMY) released topline data from Phase 3 CheckMate -8HW trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to the investigator’s choice of chemotherapy as a... 
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Exploring NYSE:BMY's dividend characteristics.
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock. 
Via Chartmill
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
The White House is endorsing a contentious power that permits the government to reclaim patents for specific  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
Why Bristol Myers Squibb Stock Is Fading Today
A high-profile clinical failure by a rival is weighing on the drugmaker's shares today. 
Via The Motley Fool
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Dirt-Cheap Stocks That Could Skyrocket
Low valuations don't always guarantee gains are in the offing. You need a company firing on all cylinders, too. 
Via The Motley Fool
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
From Bristol Myers Squibb
Via Business Wire
Can Bristol Myers Squibb Keep Its Streak Alive?
Bristol Myers Squibb is a $100 billion market cap pharmaceutical company that has raised its dividend every year since 2010 and has paid one since 1933. 
Via Talk Markets
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
3 stocking stuffers you can buy for yourself
These low-beta, deep-value high-yielding stocks are perfect stocking stuffers, even if you buy them for yourself. Rebound is expected in 2024. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
RNA stock is jumping over 15% in early trading after Avidity announced its expanded alliance with Bristol-Myers Squibb. 
Via InvestorPlace
Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
Avidity Biosciences Inc (NASDAQ: RNA) announced a global licensing and research collaboration with Bristol Myers Squibb & Co (NYSE: BMY) focused on discovering, developing, and commercializing multiple... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. 
Via InvestorPlace
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
Sometimes the stock market offers its own version of Black Friday deals. 
Via The Motley Fool
$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
While circumstances may seem relatively normal now, astute investors may want to consider reliable stocks just in case. 
Via InvestorPlace
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade
Dutch Bros stock is getting a boost on Monday after JPMorgan analyst John Ivankoe weighed in on BROS shares with an upgrade. 
Via InvestorPlace
Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering
Uber stock is moving on Monday as investors react to a $1.2 billion convertible senior notes offering and plans for the funds. 
Via InvestorPlace
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.